Open Nav

Immunomic Therapeutics, Inc.

  • Bill Hearl, Immunomic Therapeutics, Inc.

Re-introduce Immunomic Therapeutics and its current focus on oncology to the investment community

  • Date:Thursday, October 18
  • Time:9:45 AM - 10:00 AM
  • Room:Elizabethan D
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the LAMP-based nucleic acid immunotherapy platforms. These investigational technologies have the potential to alter how we use immunotherapy for cancer, allergies and animal health. ITI has entered into a significant licensing agreement with Astellas Pharma Inc. to explore the use of LAMP-Vax, the precursor to UNITE, an immunotherapy platform, for use in the prevention and treatment of allergic diseases. For information about ITI and UNITE technology, visit www.immunomix.com.
  • Company Website:www.immunomic.com
  • Company HQ City:Rockville
  • Company HQ Country:United States
  • Company HQ State:Maryland                  
  • CEO/Top Company Official:Dr. Bill Hearl
  • Year Founded:2006
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development :Autologous dendritic cell therapy in glioblastoma
  • Development Phase of Primary Product:Phase II
  • Total Amount Raised to Date, In All Rounds:25M
Speakers
Bill Hearl
Immunomic Therapeutics, Inc.
Back